Applications published 25 February 2009

A method to reduce the symptoms of heartburn and gastro-oesophageal reflux disease (GERD) by specific polysaccharides
Frutarom Netherlands 2026763*

A sustained-release intraocular implant comprising a vasoactive agent
Allergan 2026765*

Tablet compsn with a prolonged release of tamsulosin
Synthon 2026766*

Production of enveloped pharmaceutical dosage forms
Abbott 2026767*

Multiple unit pharmaceutical formulation
Dexcel Pharma Technologies 2026768*

Bilayer tablet for preventing cardiovascular events
Ferrer Internacional 2026769*

Pharmaceutical formulations and compsns of a selective antagonist of either CXCR2 or both CXCR1 and CXCR2 and methods of using the same for treating inflammatory disorders
Schering 2026770*

Microspheres comprising nanocapsules containing a lipophilic drug
Yissum Research Development Company of the Hebrew University of Jerusalem 2026771*

Nanoparticles of chitosan and hyaluronan for the adminstration of active molecules
Advanced In Vitro Cell Technologies 2026772*

Methods of modulating epithelial-mesenchymal transition and mesenchymal-epithelial transition in cells and agents useful for the same
merest Science 2026773*

Improved method of treatment of bacterial infections
ethnography 2026774*

Use of SYKES Tyrosine kinase inhibitors for the treatment of cell proliferative disorders
New Era 2026775*

• Methods of regulating expression of genes or of gene products using substituted tetracycline compounds
partake Pharmaceuticals 2026776*

• Peripheral and neural inflammatory crosstalk
University of Rochester 2026777*

• Use of a RARE antagonist or inverse agonist for the treatment of chemotherapy and/or radiation therapy side effects
Vitae Pharmaceuticals 2026778*

• Use of a compsn consisting of a combination of hydroquinone, fluocinolone acetonide and tretinoin, intended for treatment signs of photo aging of the skin
Galderma 2026779*

• Compsn for the treatment of resistant cancers comprising oridonin
Activephyto Technologies 2026780*

• Pharmaceutical preparation based on myrtucommulone A for the selective tumour and cancer therapy
Eberhard Karls Universitaet Tuebingen 2026781*

• N1,N4-bis(buta-1,3-dienyl)butane-1,4-diamine pharmaceutical compsns and uses thereof
Wisconsin Alumni Research Foundation 2026782*

• Method for enhancing cognitive function
Wyeth 2026783*

• Aerosol formulation containing ipratropium bromide and salbutamol sulphate
Boehringer Ingelheim International; Boehringer Ingelheim Pharma 2026784*

• Propellant-free inhalation aerosol formulation containing ipratropium bromide and salbutamol
Boehringer Ingelheim International; Boehringer Ingelheim Pharma 2026785*

• Use of choline-based preparations for the treatment of tinnitus
Artmed 2026786*

• Tablet formulation comprising repaglinide and metformin
Novo Nordisk 2026787*

• Therapeutic combination for painful medical conditions
Schwarz Pharma 2026788*

• Novel formulation, oriented to tumour physiology, of a cytostatic, in particular of cis-platinum
Albupharm Heidelberg 2026789*

• Co-therapy for the treatment of epilepsy and related disorders
Janssen Pharmaceutica 2026790*

• Maternal supplement
Nestec 2026791*

• Low dose doxepin formulations, including buccal, sublingual and fastmelt formulations, and uses of the same to treat insomnia
Somaxon Pharmaceuticals 2026792*

• Use of escitalopram for improving cognition
H Lundbeck 2026793*

• Xanthone derivative for the treatment of muscular disorders
DSM  2026794*

• Antimalarial therapy using a combination of synthetic artemisinin derivative and bisquinoline derivative
Ranbaxy Laboratories 2026795*

• Use of a vasopeptidase inhibitor for the treatment of pulmonary hypertension
Bioproject 2026796*

• Method for treating non-Hodgkin's lymphoma
Synta Pharmaceuticals 2026797*

• Pharmaceutical compsns comprising CBX cannabinoid receptor modulators and potassium channel modulators
Solvay Pharmaceuticals 2026798*

• Imidazolidine derivatives, uses therefor, preparation thereof and compsns comprising such
Galapagos SAS 2026799*

• Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
Novartis 2026800*

• Method of treatment of hereditary hemochromatosis
Novartis; Novartis Pharma 2026801*

• JNK inhibitors for treatment of skin diseases
Laboratoires Serono 2026802*

• Compsns of R(+) and S(-) pramipexole and methods of using the same
Knopp Neurosciences 2026803*

• Ibudilast for inhibiting macrophage migration inhibitory factor (MIF) activity
Avigen 2026804*

• Pharmaceutical combinations of diazole derivatives for cancer treatment
Astex Therapeutics 2026805*

• Use of VX-702 for treating rheumatoid arthritis
Vertex Pharmaceuticalss 2026806*

• Use of parasympatholytic substances to enhance and accelerate stem cell differentiation, related method and compsns
Universita" Degli Studi di Torino 2026807*

• Combination therapy for the treatment of cancer
AstraZeneca 2026808*

• Reversion of malignant phenotype with 9-hydroxy ellipticine derivatives
BioAlliance Pharma; Ecole Normale Superieure de Cachan; Centre National de la Recherche Scientifique-CNRS 2026809*

• Compsn and methods for modulating the immune system
Prendergast, Patrick 2026810*

• Pyrazolo [3,4-D]pyrimidine derivatives useful to treat respiratory disorders
Novartis 2026811*

• Use of 1,7-dimethylxanthine for the manufacture of a non-axiogenic psychoanaleptic drug for the treatment of neuropsychiatric disorder
Pierre Fabre Medicament; Universite de Rouen 2026812*

• 5HT receptor mediated neurogenesis
Braincells 2026813*

• Mirtazapine for the treatment of neuropathic pain
NV Organon 2026814*

• Controlled release preparations for oxcarbazepine having sigmoidal release profile
Supemus Pharmaceuticals 2026815*

• Treprostinil administration using a mediated dose inhaler
United Therapeutics 2026816*

• Use of drospirenone for preventing high blood pressure in prehypertensive patients
Bayer Schering Pharma 2026817*

• Combination of anti-inflammatory steroids having transporter-enhanced corticosteroid activity
Bodor, Nicholas S 2026818*

• Prevention and/or treatment of neurodegenerative disorders
Ulive Enterprises 2026819*

• Compsns comprising chitin microparticles and their medical uses
CMP Therapeutics 2026820*

• Hyaluronic acid binary mixtures and therapeutic use thereof
Gobbo, Sandra; Petrella, Robert 2026821*

• Topical treatment for diseases of the eye surface
Therakine 2026822*

• Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
DA Volterra 2026823*

• Multifunctional blood substitute
The United States of America as represented by the Secretary of the Navy 2026824*

• Furanone-initiated polymers
Tyco Healthcare Group 2026825*

• Probiotic microorganism compsns, granules containing them, method for the preparation thereof and uses thereof
Lesaffre et Compagnie 2026826*

• Use of ginsenosides and extracts containing them
Bayer Consumer Care 2026827*

• Use of at least one polyphenol for promoting eye health
The Iams Company 29026828*

• Method and compound for the treatment of valvular stenosis
Institut de Cardiologie de Montreal 2026829*

• Peptides modulating the activity of macrophages, useable for the treatment of rheumatoid arthritis
Universite Paul Sabatier 2026830*

• Methods and compsns for treating and preventing peripheral nerve damage
The Children's Medical Centre 2026831*

• Cladribine regimen for treating multiple sclerosis
Laboratoires Serono 2026832*

• Methods for inhibiting cardiac PAI-1
Sobel, Burton 2026833*

• Nasal and buccal systems for controlling snoring
Omega Pharma Capital 2026835*

• Peptide therapy
The University of Birmingham 2026836*

• Antibodies as T cell receptor mimics, methods of production and uses thereof
Receptor Logic 2026837*

• A method for delivering a human chorionic gonadotropin (hCG) vaccine for long-acting antibody production
Royer Biomedical 2026838*

• RNA virus vaccines and methods
The Board of Regents of the University of Oklahoma 2026839*

• Targeted imaging and/or therapy using the [3+2]-azide-alkyne cycloaddition
Koninklijke Philips Electronics 2026840*

• Conjugation process for PNAG and a carrier protein
GlaxoSmithKline Biologicals; the Brigham and Women's Hospital 2026841*

• N-terminal modified PEG-trail, method for preparing and uses thereof
Sungkyunkwan University Foundation for Corporate Collaboration; Nexentech 2026842*

• Therapeutic uses of inhibitors of RTP801L
Quark Pharmaceuticals 2026843*

• Novel imaging agents
GE Healthcare Ltd; GE Healthcare AS 2026844*

• Novel therapeutic and diagnostic products and methods
The Rockefeller University 2026845*

• A polymer matrix, uses thereof and a method of manufacturing the same
Bactiguard 2026846*